Serial first- and second-trimester Down's syndrome screening tests among IVF- versus naturally-conceived singletons

Human Reproduction

Volumn 17, Issue 4, 2002, Pages 1081-1085

  Maymon, R ^a,c   Shulman, A ^b,c  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Assisted reproduction; Combined test; Down's syndrome; Triple test

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONCEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DOWN SYNDROME; FEMALE; FERTILIZATION IN VITRO; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATION PERIOD; HUMAN; INFERTILITY THERAPY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALFORMATION SYNDROME; SCREENING TEST; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; STATISTICAL SIGNIFICANCE;

EID: 0036109145     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.4.1081     Document Type: Article

References (38)

1. Test screening in in vitro fertilization pregnancies
2. Down's syndrome screening marker levels following assisted reproduction
3. Nuchal translucency measurements: Frequency distribution and changes with gestation in a general population
4. Delayed luteo-placental shift of progesterone production in IVF pregnancy
5. Antenatal screening
6. First-trimester screening for Down syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy - The combined test
7. Early pregnancy screening for fetal aneuploidy with markers and nuchal translucency
8. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies
9. Inaccurate estimation of risk in second trimester serum screening for Down's syndrome among women who have already had first trimester screening
10. Assessment of the value of reporting partial screening results in prenatal screening for Down's syndrome
11. Screening of maternal serum for fetal Down's syndrome in the first trimester
12. Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down's syndrome screening
13. On-to-on versus on-to-out nuchal translucency measurements
14. Combined first-trimester nuchal translucency and second-trimester biochemical screening tests among normal pregnancies
15. Maternal serum screening for Down syndrome in pregnancies conceived by intra-uterine insemination
16. Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in vitro fertilization
17. Application to early sonographic marker of Down syndrome to pregnancies achieved by assisted reproduction techniques
18. Screening for Down syndrome in the second trimester of pregnancy
19. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction
20. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies
21. Antenatal screening for Down's syndrome in reproductive pregnancies
22. Comparison of nuchal translucency measurement and second-trimester triple serum screening in twin versus singleton pregnancies
23. Comparison of nuchal translucency measurement and midgestation serum screening in assisted reproduction versus naturally conceived singleton pregnancies
24. Sequential first and second trimester screening tests: Correlation of the markers' levels in normal versus Down's syndrome affected pregnancies
25. Prospective maternal serum human chorionic gonadotropin screening for the risk of fetal chromosome anomalies and the subsequent fetal and neonatal death
26. Serum screening for Down syndrome and adverse pregnancy outcome: A case-controlled study
27. First trimester maternal serum free β human chorionic goandotropin and pregnancy associated plasma protein A as predictors of pregnancy complications
28. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation
29. Maternal midtrimester serum APF and free β-hCG levels in in vitro fertilization twin pregnancies
30. Maternal serum screening for fetal Down syndrome in IVF pregnancies
31. The best donor
32. UK multicenter project on assessment of risk of trisomy 21 by maternal age and nuchal translucency thickness at 10-14 weeks of gestation
33. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A
34. Combining ultrasound and biochemistry in first-trimester screening for Down syndrome
35. Antenatal screening for Down's syndrome
36. Serum markers for Down's syndrome in women who have had in vitro fertilisation: Implications for antenatal screening
37. Integrated screening for Down syndrome based on tests performed during the first and second trimesters
38. First trimester screening for Down syndrome and assisted reproduction: No basis for concern